Can You Give Glucagon IV? Key Product Attributes & Usage Guide
Abstract: Intravenous (IV) glucagon administration is clinically viable for severe hypoglycemia, leveraging its peptide hormone structure (29 amino acids) for rapid glycemic response. Market trends show a 7.2% CAGR (2023–2030) driven by diabetes prevalence and biosimilar adoption. Brand comparison reveals Lilly’s Glucagon® (FDA-approved, stable lyophilized powder) vs. Xeris’s Gvoke® (ready-to-use liquid, reduced reconstitution errors). IV glucagon’s technical advantage includes immediate bioavailability; drawbacks include short shelf-life (24 months) and need for cold-chain logistics (2–8°C). Product parameters: potency ≥95% purity, pH 3.5–4.5. Applications extend to diagnostic gastrointestinal motility studies. Industry status: dominated by Novo Nordisk and Eli Lilly, with strict GMP certifications (cGMP, ISO 9001). Selection tips prioritize stability data, reconstitution time (<1 min), and supplier’s cold-chain audit trail.